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Background. Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by bone erosions and new bone formation.
MicroRNAs (miRNAs) are key regulators of the immune responses. Differential expression of miRNAs has been reported in
several inflammatory autoimmune diseases; however, their role in PsA is not fully elucidated. We aimed to identify miRNA
expression signatures associated with PsA and to investigate their potential implication in the disease pathogenesis. Methods.
miRNA microarray was performed in blood cells of PsA patients and healthy controls. miRNA pathway analyses were performed
and the global miRNA profiling was combined with transcriptome data in PsA. Deregulation of selected miRNAs was validated by
real-time PCR. Results. We identified specific miRNA signatures associated with PsA patients with active disease. These miRNAs
target pathways relevant in PsA, such as TNF, MAPK, and WNT signaling cascades. Network analysis revealed several miRNAs
regulating highly connected genes within the PsA transcriptome. miR-126-3p was the most downregulated miRNA in active
patients. Noteworthy, miR-126 overexpression induced a decreased expression of genes implicated in PsA. Conclusions. This
study sheds light on some epigenetic aspects of PsA identifying specific miRNAs, which may represent promising candidates as
biomarkers and/or for the design of novel therapeutic strategies in PsA.
1. Introduction
Psoriatic arthritis (PsA) is characterized by inflammation of
entheses and synovium, eventually leading to joint erosions
and new bone formation [1].
PsA affects 10% to 30% of patients with skin psoriasis,
with an estimated prevalence of 1% in the general population.
Despite its association with skin psoriasis, PsA is considered
a distinct clinical entity with a strong heritable component
[2] and many genes have been implicated in conferring
susceptibility to the disease [3]. However, only a limited
number of genes have been linked to both psoriasis and PsA
[3]. Several criteria have been proposed for the diagnosis and
classification of PsA. Although none of them are universally
accepted, the classification criteria proposed by Moll and
Wright [4] and the more recent classification criteria for PsA
(CASPAR) [5] are the most widely used.
The diagnosis of PsA is mainly performed on clinical
features after the exclusion of other seronegative arthritides
and no diagnostic tests are available so far.
The synovial tissue in PsA is characterized by an abundant
T-cell infiltrate, by marked angiogenesis, and by synovial
hyperplasia with increased secretion of cytokines and pro-
teases, which may amplify the local inflammatory process
eventually leading to joint destruction [6]. The cytokine
tumor necrosis factor-alpha (TNF-alpha) is a very important
inflammatorymediator and has been implicated in the patho-
genesis of articular damage in PsA [6]. TNF-alpha inhibitors
are therefore widely used in PsA therapy and are usually
quite effective in reducing the extent of skin lesions and of
musculoskeletal symptoms; however, a high percentage of
PsA patients does not respond to TNF-alpha antagonists [1,
7].Therefore, other cytokines have recently become targets of
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biological agents such as interleukin-12 (IL-12), interleukin-
23 (IL-23), and interleukin-17 (IL-17) [1, 7].
At present, there are no specific markers that can help in
the diagnostic workup and that can predict disease progres-
sion and therapeutic response. Moreover, a biomarker able
to distinguish between different clinical phenotypes of PsA
or that could be used as a predictive marker for future PsA
development in patients with psoriasis is still lacking.
In our previous work, for the first time we analyzed the
transcriptome in paired synovial tissue and peripheral blood
cells of patients with PsA [8]. The upregulation of Th17 cells
related genes and of type I interferon (IFN) inducible genes
in PsA patients strengthened the hypothesis that PsA is of
autoimmune origin, since the coactivity of IFN and Th17
pathways is typical of autoimmunity [8]. Importantly, the
study showed that a large number of genes were similarly
modulated in blood and synovial tissue, indicating that blood
may be a significant promise for gene expression studies as
substitute of tissues that are not easily accessible [8].
MicroRNAs (miRNAs) are small noncoding RNAs that
play an important role in the regulation of various biological
processes through their interaction with cellular messen-
ger RNAs [9]. Inflammatory responses have an impact on
miRNAs expression, regulating their biogenesis by altering
the transcription and processing of precursor transcripts or
influencing stabilization of mature miRNAs [9]. In recent
years, the number of miRNAs implicated in immune system
development and function has dramatically enhanced, and
there has been widespread discussion of their potential use
as therapeutics for immunological diseases [9]. The concept
that miRNAs participate in the pathogenesis of diseases,
especially refractory diseases with unidentified mechanisms,
might lead to a novel effective treatment. A number of studies
have reported differential expression of miRNAs in several
inflammatory autoimmune diseases, such as in rheumatoid
arthritis (RA), multiple sclerosis, systemic lupus erythe-
matosus, psoriasis, and systemic sclerosis [10]. These studies
highlighted a deep implication of miRNAs as regulatory
molecules in autoimmunity and the intriguing possibility of
using miRNAs as disease biomarkers in these immunolog-
ical disorders. In RA, miRNAs play an important role in
inflammation, synovial cell proliferation, and production of
matrix metalloproteases (MMP). Moreover, the expression
level of several miRNAs in peripheral blood mononuclear
cells (PBMC) correlates with RA disease activity [11].
As far as PsA concerns, little is known about miRNAs
expression despite the relatively high prevalence of the
disease. To date, only a study has explored blood miRNAs
expression profile in a cohort of early active PsA patients
[12]. Nevertheless, no high-throughput miRNA expression
studies have been conducted to identify miRNAs specifically
associated with the disease activity and no study has been
so far performed which combines the analysis of blood
microRNAswith transcriptional profiles in patients with PsA.
In the present study, we performed a miRNA microarray
analysis on PBMCs of PsA patients at the active stage and
in the remission phase of the disease. We found that distinct
miRNA expression profiles are present in active and nonac-
tive PsA patients as compared to healthy controls. Moreover,
active and nonactive PsA patients are specifically identified
by two different miRNA signatures. Pathway enrichment
analysis on gene targets of deregulated miRNAs revealed
signaling pathways typically implicated in PsA, such as
TNF, mitogen-activated protein (MAP) kinase, and wingless
related integration site (WNT) cascades.
The modular analysis of differentially expressed genes
in PsA revealed pathogenetically relevant networks that
are possibly targeted by the identified miRNAs. Among
the modulated miRNAs, we found that miR-126-3p was
downregulated in active PsA patients, whereas its expression
was higher in nonactive patients. miR-126 overexpression
induced a decrease of putative molecular targets with a
potential role in PsA pathogenesis. This study sheds light
on some aspects of PsA pathogenesis identifying deregulated
miRNAs as promising candidates for the discovery of disease
biomarkers and/or as molecular tools for designing novel
therapeutic strategies in PsA.
2. Materials and Methods
2.1. Patients. We studied a cohort of 23 patients (12males and
11 females,mean age: 53.5 years) affected byPsA, attending the
Unit of Autoimmune Diseases, at the University Hospital of
Verona, Italy. All patients fulfilled theCASPAR criteria for the
diagnosis of PsA: inflammatorymusculoskeletal involvement
(inflammatory arthritis, enthesitis, or lumbar pain) combined
with at least 3 features: (1) evidence of current psoriasis,
personal history of psoriasis, and family history of psoriasis
in unaffected patients; (2) affected nails (onycholysis, pit-
ting); (3) dactylitis; (4) negative rheumatoid factor; and (5)
radiographic evidence of new juxta-articular bone formation
(excluding osteophytes) [5].
All the patients underwent clinical examination and lab-
oratory evaluation comprehensive of inflammatory markers,
such as C-reactive protein (CRP) and erythrocytes sedimen-
tation rate (ESR); rheumatoid factor (RF) and anti-cyclic
citrullinated peptide (CCP) antibody detected by ELISA test;
antinuclear antibody detected by indirect immunofluores-
cence on HeLa derived HEp-2 cells; and genetic screening
for the association with the allele HLA-B27. All patients
underwent the following instrumental investigations: ultra-
sonography with Power Doppler to investigate subclinical
enthesopathy and synovitis in asymptomatic patients, con-
ventional radiography, magnetic resonance imaging (MRI),
and scintigraphy. The radiological features of peripheral
PsA included asymmetric distribution, participation of distal
interphalangeal joints, periostitis, bone density preservation,
bone ankylosis, and pencil-in-cup deformity.
Patients were classified as active or in remission phase
using the composite index Disease Activity in Psoriatic
Arthritis (DAPSA) which takes into account the number of
tender and swollen joints, CRP levels and patients’ assessment
of general disease activity and pain using a visual analogic
score (VAS). The disease was considered in remission when
the score was <5. The patients in active phase bled before
the beginning of treatment with anti-TNF agents and/or with
disease-modifying antirheumatic drugs (DMARDs). Patients
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Table 1: Clinical characteristics of PsA patients.
Patients 23
Sex
Male 12
Female 11
Age at diagnosis 53.5 ± 9.3
Involvement
Axial 6
Peripheral 17
Enthesitis 11
Dactylitis 6
Psoriasis 15
Association with HLA-B27 5
Patients used for miRNA microarray study 9
Sex
Male 5
Female 4
Age at diagnosis 53 ± 4.6
Involvement
Axial 3
Peripheral 6
Enthesitis 5
Dactylitis 3
Psoriasis 6
Association with HLA-B27 4
in remission were in maintenance treatment with biological
agents and/or DMARDS.
A group of 9 subjects was selectedwithin the entire cohort
of PsA patients and utilized for the miRNAmicroarray study.
The clinical features of the patients are reported in Table 1
that also includes a description of the PsA patients selected
for the microarray study. 15 control healthy subjects matched
for sex and age served as control group (7 males, 8 females).
Moreover, 7 patients with rheumatoid arthritis (RA) were
used as controls. RA patients had the American College of
Rheumatology classification criteria for RA [13]. In all RA
patients, the disease was at an active stage and blood was
obtained before therapy with biological agents.
All the participants to the study signed awritten informed
consent. The local Ethical Committee of the University
Hospital ofVerona,Verona, Italy, had approved the study pro-
tocol. All the investigations have been performed according
to the principles contained in the Helsinki declaration.
2.2. Microarray Analysis. Blood samples were collected in
BD Vacutainer K
2
EDTA tubes using a 21-gauge needle.
PBMCwere obtained upon stratification on Lympholyte cell
separation density gradient (Cedarlane, Burlington, Canada).
Total RNA extraction from PBMCs was performed with
miRNeasy mini kit following manufacturer’s protocol (Qia-
gen GmbH, Hilden, Germany). Samples hybridization and
scanning were performed with miRNA Complete Labeling
and Hyb Kit Protocol manual following the manufacturer
provided protocols (Agilent Technologies, SantaClara, CA,
USA), by the Cancer Genomics Laboratory of Edo ed Elvo
Tempia Valenta foundation (Fondazione Edo ed Elvo Tempia
Valenta, Biella, Italy). SurePrint Human miRNA Microarray
Kit Release 21.0, 8x60K (Agilent Technologies), containing
probes for 2549 miRNAs, was used. The Gene Spring soft-
ware, version 14.8 (Agilent Technologies, SantaClara, CA,
USA), was used to background-adjust, normalize, and log-
transform signals intensity. Quantile was used for between-
array normalization. Relative miRNAs expression levels were
validated applying the unpaired 𝑡-test (𝑝 ≤ 0.01) and the
Bonferroni multiple testing correction. Finally, statistically
significantmiRNAswere chosen for final considerationwhen
their expression was at least 1.5-fold different in the test
sample versus control sample [log
2
(fold change) > |0.5|].
2.3. Pathway Enrichment Analysis of MicroRNA Targets.
Pathway enrichment analysis was performed using the
DIANA-Tarbase v. 7.0 and DIANA-miRPath server v3.0
(http://diana.imis.athena-innovation.gr) [14, 15]. miRNA tar-
get genes identified by Tarbase were processed by miRPath
to find enriched biological pathways provided by the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [15]. The
analysis was performed by using “genes union” option. A 𝑝
value threshold of 0.05 and FDR correction were applied to
the analysis. All identified pathways are arranged according
to enrichment statistical scores (𝑝 values) in addition to the
number and names ofmiRNA target genes implicated in each
KEGG pathway.
For the heat-map of Figure 3(a), the percentages of
miRNA target genes for each biological process (BP) indi-
cated were calculated as follows: the list of miRNAs targeting
the BP of interest was obtained from the Gene Ontology
(GO) reverse search function of miRPath v. 3.0. The module
presents the list of miRNAs targeting the GO term of interest
and the number of targeted genes for each miRNA (Tarbase
v7.0 method). The percentage of target genes was calculated
on the total number of human genes included in theGO term,
as obtained fromAmiGO 2 search tool in the Gene Ontology
Consortium database (http://www.geneontology.org/).
2.4. Protein-Protein Interaction (PPI) Network Construc-
tion and Modular Analysis. Differentially expressed genes
(DEGs) in PsA samples from our previous study [8] were
mapped onto the STRING database [16] to detect protein-
protein interactions (PPI) pairs validated by experimental
studies. Network and modular analysis were carried out as
we previously described [17].
2.5. Cell Cultures and Transfections. Human leukemic T-
cell lymphoblast cell line Jurkat was purchased from Euro-
pean Collection of Authenticated Cell Cultures (clone
E6.1, ECACC 88042803). Cells were cultured in Roswell
Park Memorial Institute (RPMI) medium supplemented
with 10% (v/v) fetal bovine serum (FBS, South America,
Gibco; Thermo Fisher Scientific, Wilmington, DE, USA),
L-Glutamine 1mM, penicillin (200U/mL), and streptomycin
(100mg/mL).
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Jurkat cells were transfected by electroporation with
Neon Transfection System (Thermo Fisher Scientific,
Wilmington, DE, USA). Briefly, 2 × 106 cells were electro-
porated in 100 𝜇L tips (voltage: 1410V, pulse width 30ms, 1
pulse) with 60 pmol of miRIDIAN microRNA human hsa-
miR-126-3p mimic or 60 pmol of miRIDIAN microRNA
mimic negative control #2 (Dharmacon RNA Technolo-
gies, LaFayette, CO). 48 hours after transfection, cells were
harvested and analyzed. Total RNA from Jurkat cells was
obtained with miRNeasy mini kit (Qiagen, GmbH, Hilden,
Germany).
2.6. Real-Time PCR. Mature miRNA expression was assayed
by TaqMan Advanced miRNA assays chemistry (Applied
Biosystems, Foster City, CA, USA). Briefly, 10 ng of total
RNA was reverse-transcribed and preamplified with Taq-
Man Advanced miRNA cDNA synthesis kit following man-
ufacturer’s instructions (Applied Biosystems, Foster City,
CA, USA). 5 𝜇L of 1 : 10 diluted cDNAs was amplified in
20𝜇L PCR reactions with 2x Fast Advanced Master Mix
and TaqMan Advanced miRNA assays for hsa-miR-126-
3p (477887 mir), hsa-miR-130a-3p (477851 mir), hsa-miR-
151a-5p (478505 mir), or hsa-miR-148a-3p (477814 mir). As
endogenous controls, we used hsa-miR-16-5p (477860 mir)
and hsa-miR-26a-5p (477995 mir), since they are known to
be expressed at relatively constant levels acrossmany different
tissues, including blood [18, 19]. We further confirmed stable
expression patterns formiR-16-5p andmiR-26a-5p across our
samples (data not shown). The mean of Ct for miR-16-5p
and miR-26a-5p expression was used to normalize miRNA
expression. Real-time PCR was carried out in triplicate on a
QuantStudio 6 Flex instrument (Applied Biosystems, Foster
City, CA, USA). Expression values were obtained by ΔCt
method using QuantStudio Real-Time PCR system software
v. 1.3.
For mRNA quantification in Jurkat cells, 500 ng of total
RNA was treated with 1 unit of DNase I Amplification
Grade (Invitrogen, Carlsbad, CA, USA) and then reverse-
transcribed with random primers by using Super Script
IV first-strand synthesis system following manufacturer’s
instructions (Thermo Fisher Scientific, Wilmington, DE,
USA). Real-time PCR were carried out in triplicate with
PowerUp Sybr Green reagent (Applied Biosystems, Foster
City, CA,U.S.A). Beta-Actin (ACTB)was used as endogenous
control using the ΔΔCt method for comparing relative
fold expression differences. The following primers were
used: PIK3R2 (FW: 5󸀠-CGAGACCAGTACCTCGTGTG-
3󸀠; RV: 5󸀠-ATCGTCCTCGTCCTCCATGA-3󸀠); AKT2 (FW:
5󸀠-TGTCATCAAAGAAGGCTGGCT-3󸀠; RV: 5󸀠-GGCCTC-
TCCTTGTACCCAAT-3󸀠); RANKL (FW: 5󸀠-ACACTCCAA-
AAACTGGGGCT-3󸀠; RV: 5󸀠-ACACTCCAAAAACTG-
GGGCT-3󸀠); PPP3CB (FW: 5󸀠-TCTGTTCTCAGGGAG-
GAGAGT-3󸀠; RV: 5󸀠-ACACTCCACTAGGCAACATCC-
3󸀠); SDC2 (FW: 5󸀠-CTGCCCCTAAACTTCTGCCG-3󸀠; RV:
5󸀠-TGCCGAGGTTCAGTTTCTGG-3󸀠); ACTB (FW: 5󸀠-
ACCGCGAGAAGATGACCCAGA-3󸀠; RV: 5󸀠-GGATAG-
CACAGCCTGGATAGCAA-3󸀠).
3. Results
3.1. High-Throughput miRNA Expression Profiling in PBMCs
of Psoriatic Arthritis. In order to identify miRNA expression
signatures associated with PsA, we analyzed global miRNA
expression profiles by microarray in PBMCs derived from
5 patients with an active disease (active PsA), 4 patients in
a remission phase (nonactive PsA), and 7 healthy age and
sex matched donors (healthy). The clinical characteristics
of patients included in the microarray study are reported
in Table 1. When we compared active PsA samples with
healthy controls, microarray analyses revealed 34 modulated
miRNAs that satisfied the Bonferroni-corrected 𝑝 value
criterion (p ≤ 0.01) and the fold change criterion (FC ≥ |1.5|),
showing robust and statistically significant variation between
PsA and healthy control samples. Among these 34 miRNAs,
21 were overexpressed and 13 underexpressed (Table 2). The
comparison between nonactive PsA and healthy controls
revealed 22 miRNAs significantly deregulated with 14 and
8 miRNAs over- and underexpressed, respectively (Table 3).
The hierarchical clustering based on the significantly dereg-
ulated miRNAs showed a clear separation between active
or nonactive PsA and healthy control groups, respectively
(Supplementary Figure 1).
The lists of deregulated miRNAs in active and in nonac-
tive PsA showed a partial overlap, with 12miRNAs commonly
deregulated in PsA samples. Moreover, all the overlapping
miRNAs showed consensual modulation being over- or
underexpressed in both active and nonactive disease (named
PsA common subset). On the contrary, 22 miRNAs are
differentially expressed only in active PsA (PsA only active),
whereas 10 miRNAs were deregulated only in nonactive
PsA samples (PsA only nonactive). These three subsets of
differentially expressed miRNAs are listed in Figure 1.
3.2. Pathway Enrichment Analysis of miRNAs Deregulated
in PsA. To investigate the molecular pathways potentially
targeted by deregulated miRNAs in PsA, we performed a
bioinformatic analysis using the miRNA pathway analysis
web-server DIANA-miRPath v.3 [15]. The software allows
assessing the miRNA regulatory roles and the identification
of controlled pathways based on predicted and/or validated
miRNA target interactions. Since a major obstacle in the
estimation of the functional impact of miRNAs on pathways
is a high false discovery rate of miRNA target prediction
algorithms, we focused our analyses only on experimentally
validated miRNA targets included in DIANA-Tarbase v. 7.0
[14].
Thus, based on the validated gene targets, we performed
KEGG molecular pathway analyses in the three previously
identified subsets of differentially expressed miRNAs: PsA
only active, PsA only nonactive, and PsA common. Of note,
in all the miRNAs subsets we found a significant enrichment
in several pathways that have been already described in PsA,
such as pathways associated with proteoglycans metabolism
[20]. Other KEGG pathways, significantly enriched, were
related to the immune system and to signaling path-
ways regulating cell proliferation and/or apoptosis. These
selected KEGG pathways for each miRNA subset are shown
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Table 2: Differentially expressed miRNAs in PBMC from PsA patients with active disease compared to healthy controls.
MicroRNA systematic name miRBase accession number Regulation Fold change (log
2
) 𝑝 (corr)
hsa-miR-126-3p MIMAT0000445 Down −7.4133115 0.00008
hsa-miR-151a-5p MIMAT0004697 Down −5.9333086 0.00017
hsa-miR-130a-3p MIMAT0000425 Down −5.849619 0.00831
hsa-miR-4741 MIMAT0019871 Up 5.8378386 0.00705
hsa-miR-199a-3p MIMAT0000232 Down −5.6022415 0.01055
hsa-miR-451a MIMAT0001631 Down −5.4353294 0.01515
hsa-miR-3196 MIMAT0015080 Up 4.804034 0.01327
hsa-miR-575 MIMAT0003240 Up 4.670869 0.00992
hsa-miR-3135b MIMAT0018985 Up 4.960381 0.00047
hsa-miR-574-5p MIMAT0004795 Up 4.676454 0.00218
hsa-miR-638 MIMAT0003308 Up 4.598291 0.00620
hsa-miR-4687-3p MIMAT0019775 Up 4.52379 0.01118
hsa-miR-2861 MIMAT0013802 Up 4.510478 0.01528
hsa-miR-199a-5p MIMAT0000231 Down −4.415467 0.00940
hsa-miR-664b-5p MIMAT0022271 Up 4.3418427 0.00586
hsa-miR-148a-3p MIMAT0000243 Down −3.969935 0.00551
hsa-miR-4787-5p MIMAT0019956 Up 3.953499 0.00467
hsa-miR-192-5p MIMAT0000222 Down −3.6372743 0.01136
hsa-miR-186-5p MIMAT0000456 Down −3.226546 0.01406
hsa-miR-6869-5p MIMAT0027638 Up 3.2232947 0.00181
hsa-miR-423-5p MIMAT0004748 Down −2.1335235 0.01245
hsa-miR-7704 MIMAT0030019 Up 2.0383425 0.00340
hsa-miR-6089 MIMAT0023714 Up 2.0341978 0.00464
hsa-miR-6775-5p MIMAT0027450 Up 1.9994686 0.01461
hsa-miR-6125 MIMAT0024598 Up 1.9778519 0.00284
hsa-miR-1202 MIMAT0005865 Up 1.6242537 0.01527
hsa-miR-331-3p MIMAT0000760 Down −1.4172684 0.01484
hsa-miR-4530 MIMAT0019069 Up 1.4045066 0.00092
hsa-miR-6749-5p MIMAT0027398 Up 1.3433247 0.00744
hsa-miR-4516 MIMAT0019053 Up 1.1387029 0.00619
hsa-miR-4281 MIMAT0016907 Up 1.0670805 0.00732
hsa-miR-6821-5p MIMAT0027542 Up 0.9847684 0.01431
hsa-miR-92a-3p MIMAT0000092 Down −0.6512084 0.00370
hsa-miR-17-5p MIMAT0000070 Down −0.59740776 0.01058
in Figure 2(a). The complete lists of significantly enriched
KEGG pathways are reported in Supplementary Tables 1–3.
Interestingly, we found that TNF, MAPK, and WNT
signaling pathways were specifically enriched exclusively
in the PsA only active subset (Figure 2(a)), whereas they
were not significantly overrepresented in the other miRNA
subsets. We further focused our attention on TNF signal-
ing genes targeted by the PsA only active miRNA subset.
Within this subset, several miRNAs target key molecules
of TNF signaling pathway. For example, miR-130a-3p has
been reported to target TNF-alpha [21] as well as CREB
transcription factor, a downstream mediator of TNF stim-
uli [22]. MiR-192-5p and miR-199a-5p target IL-6, IL-15,
and LIF, key proinflammatory effectors induced by TNF
[23]. Furthermore, miR-130a, miR-148a-3p, miR-192a-5p,
miR-199a-3p, and miR-126-3p target NF-KB1 and MAPK
components. MAP kinases are targets of PsA only active
miRNAs: for example, MAPK1, MAP2K3, MAP3K4, and
MAP4K3 were reported as miR-148a-3p targets [24–27].
Moreover, we also identified several miRNA target genes
belonging to the WNT/beta-catenin pathway: among PsA
only active miRNAs, miR-130a-3p targets WNT10B, whereas
miR-192-3p targets WNT3. Furthermore, some members of
the “frizzled” gene family, transmembrane domain proteins
that are receptors for WNT signaling proteins, such as FZD1,
FZD4, and FZD7, are targets of miR-192-5p, whereas miR-
130a-3p interacts with FZD3 [26]. A complete description
of deregulated miRNAs and their target genes included in
the TNF, MAPK, and WNT signaling pathways is shown in
Supplementary Tables 4–6.
Interestingly, the KEGG pathway “proteoglycans in can-
cer” was overrepresented in all the miRNA subsets studied.
6 BioMed Research International
Table 3: Differentially expressed miRNAs in PBMC from PsA patients with nonactive disease compared to healthy controls.
MicroRNA systematic name miRBase accession number Regulation Fold change (log
2
) 𝑝 (corr)
hsa-miR-4741 MIMAT0019871 Up 6,5892735 0,00002
hsa-miR-638 MIMAT0003308 Up 4,598291 0,00620
hsa-miR-574-5p MIMAT0004795 Up 3,7202826 0,00412
hsa-miR-1268b MIMAT0018925 Up 3,6815526 0,00343
hsa-miR-3135b MIMAT0018985 Up 3,4817348 0,00328
hsa-miR-6869-5p MIMAT0027638 Up 2,1804085 0,00020
hsa-miR-28-5p MIMAT0000085 Down −1,8294334 0,00498
hsa-miR-7704 MIMAT0030019 Up 1,5352136 0,00430
hsa-miR-590-5p MIMAT0003258 Down −1,3467566 0,00799
hsa-miR-6125 MIMAT0024598 Up 1,3346127 0,00003
hsa-miR-423-5p MIMAT0004748 Down −1,2536168 0,00206
hsa-miR-6089 MIMAT0023714 Up 1,2348151 0,00002
hsa-miR-342-5p MIMAT0004694 Down −1,0435429 0,00629
hsa-miR-4530 MIMAT0019069 Up 0,8868689 0,00014
hsa-miR-4516 MIMAT0019053 Up 0,81782526 0,00078
hsa-miR-361-5p MIMAT0000703 Down −0,79595757 0,00558
hsa-miR-320c MIMAT0005793 Down −0,7949343 0,00350
hsa-miR-4505 MIMAT0019041 Up 0,69223696 0,00009
hsa-miR-1202 MIMAT0005865 Up 0,6756515 0,00419
hsa-miR-6087 MIMAT0023712 Up 0,59775305 0,00288
hsa-miR-146a-5p MIMAT0000449 Down −0,59278536 0,00388
hsa-miR-320d MIMAT0006764 Down −0,5812883 0,00013
However, it is important to note that it was the top enriched
pathway in PsA only active,whereas its enrichment in the two
other subsets was less prominent. Interestingly, the number
of miRNA target genes in this pathway was much higher in
PsA only active as compared to the other miRNAs subsets
(Figure 2(b)).
These target genes included AKT1, FGF2, WNT3,
WNT5A, andTWIST2.The entire lists ofmiRNA target genes
that are members of the proteoglycans in cancer pathway are
reported in Supplementary Table 7.
3.3. Comparison of Deregulated miRNAs with Differentially
Expressed Genes in PsA. In a previous work, we investigated
PsA-associated transcriptional profiles by a gene expression
analysis of peripheral blood cells and synovial biopsies
derived from paired PsA patients and identified genes mod-
ulation strictly connected to the disease pathogenesis [8].
In this study, we aimed to complement this gene expression
analysis detecting modulated miRNAs that may target dif-
ferentially expressed genes (DEGs) identified in our previous
analysis.
To this purpose, the list of miRNAs targets was compared
to the list ofDEGs identified in blood samples of PsApatients.
Since in our previous study we had enrolled patients with
an active disease, for this comparison we excluded target
genes of the PsA only nonactive miRNA list. According to
Tarbase, we observed that the ∼43% of these PsA-associated
DEGs were targeted by deregulated miRNAs identified in the
present study. We found that 24.9% of these genes showed an
opposite modulation with respect to their targeting miRNAs
(Figure 3(a)).
Interestingly, we found that several downmodulated
miRNAs, such as miR-130a-3p, miR-126-3p, and miR-192-
5p, targeted crucial molecules upregulated in PsA. Indeed,
miR-130a-3p targetedTNF-alpha,miR-126-3p targeted osteo-
pontin (SPP1) [28], and both miR-130a-3p and miR-192-5p
targeted interleukin-6 signal transducer molecule (IL-6ST).
Notably, miR-126-3p was the most downregulated miRNA in
our PsA patients.
The complete list of DEGs inversely deregulated with
respect to their associated targeting miRNAs is shown in
Supplementary Table 8.
Our previous gene expression study in PsAwas then com-
plemented by amore sophisticated network analysis in which
the functional interactions between the protein products of
modulated genes have been evaluated. By this approach, a
protein-protein interaction (PPI) network comprising 291
genes (nodes) and 535 pairs of interactions (edges) was
constructed (Figure 3(b)).
The obtained PPI-network was submitted to a modular
analysis to highlight clusters of densely interconnected nodes
(modules) that are expected to be involved in common
biological processes and to have a prominent role in the
disease pathogenesis. This analysis detected the presence of
five modules (k = 5) that are graphically represented in Fig-
ure 3(c). For each module, a functional enrichment analysis
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Figure 1: Overlap of deregulated miRNAs in active and nonactive PsA patients. Venn diagram representing the overlap between significantly
deregulated miRNAs in PsA active and in nonactive patients. Deregulated miRNAs belonging to the three subsets identified as “PsA only
active,” “PsA common,” and “PsA only nonactive” are listed.
was performed to identify the most represented biological
classes and signaling pathways. We found that the most
enriched biological processes (BP) included glycosaminogly-
can catabolic process (module M0, p value < 0.0001), type I
interferon signaling (module M1, p value < 0.0001), inflam-
matory response (moduleM2, p value < 0.0001), extracellular
matrix organization (module M3, p value < 0.0001), and
positive regulation of activated T-cell proliferation (module
M4, p value = 0.0026). Interestingly, in module M2 the “T-
helper 17 cell immune response” process was significantly
enriched (p value = 0.0151). Indeed, in this module we found
the presence of several Th-17 cells associated genes including
C-X-C motif chemokine ligand 1, 2, and 13 (CXCL1, 2, and
13), TNF, interleukin-8, 17A, 18, and 23A (IL8, 17A, 18, and
23A), C-C chemokine receptor type 6 (CCR6), C-C motif
chemokine ligand 20 (CCL20), secreted protein acidic and
cysteine rich (SPARC), interleukin-12 receptor subunit beta-
1 (IL12RB1), matrix metalloproteinase-9 (MMP9), and signal
transducer and activator of transcription 3 (STAT3).
Moreover, we also have to mention that in module M4
we observed an enrichment in the “positive regulation of T-
helper 17 cell lineage commitment” BP (p value = 0.0164)
due to the presence of Th-17 cells related genes such as
IL12RB1, IL23A, and STAT3. Furthermore, with agreement
to the TNF-driven inflammatory response typical of PsA,
we found the enrichment of “positive regulation of tumor
necrosis factor production” BP in module M4 (p value =
0.0267). Several pathways were also enriched in the five
modules, including Toll-like receptor (module M1, p value =
0.0310), inflammation mediated by chemokine and cytokine
(module M2, p value < 0.0001), integrin (module M3, p
value < 0.0001), and interleukin (module M4, p value <
0.0001) signaling pathways. Noteworthy, in module M4 we
observed the enrichment of p38 MAPK and B-cell activation
signaling pathways (p values< 0.0002 and 0.037, resp.). All the
enriched functional categories for each module are shown in
Supplementary Table 9.
Notably, we observed that several upregulated genes
present in various modules were also targets of modulated
miRNAs in PsA samples, including SDC2 (M0), SDC4 (M0,
M3), IFIH1 (M1), CXCL2 (M2),MMP9 (M2), SPP1 (M2,M3),
COL4A3 (M3) and LAMC1 (M3), and IL6ST (M4).
All the genes targeted in themodules by deregulatedmiR-
NAs are highlighted in Figure 3(c). Interestingly, we observed
that M0 and M3 modules included a higher percentage of
“nodes” targeted by miRNAs, with 75% and 70% of targeted
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Figure 2: Pathway enrichment analysis for deregulatedmiRNAs in PsA. (a) Histograms representing enrichment 𝑝 values for selected KEGG
pathways obtained by DIANA-miRPath v.3 software analysis. Functional analyses were conducted for the PsA only active, PsA only nonactive,
and PsA commonmiRNA list. Overrepresentation statistical analysis was performed for the union of targeted genes by miRNA lists (“Genes
Union” option) based on TARBASE 7.0. (b) Enrichment analysis comparison between miRNA subsets for the KEGG pathway “proteoglycans
in cancer.” Enrichment 𝑝 value, number of genes targeted (#genes), and number of miRNAs (#miRNAs) for each subset are shown.
genes, respectively. The main biological processes associated
with M0 and M3 included glycosaminoglycan metabolism
(M0) and extracellular matrix organization (M3).
3.4. Biological Processes Altered in PsA Are Targeted by
Deregulated miRNAs in Active Disease. Since the PsA only
active miRNA subset was specifically associated with the
active disease, we decided to further study this subset to
identifymiRNAs potentially relevant in PsA pathogenesis. To
this purpose, we selected Gene Ontology (GO) terms from
Biological Process Ontology representing functional classes
altered in PsA and we verified whether they were targeted
by PsA only active miRNAs. The choice of GO terms was
based on the functional classes that we found altered by gene
expression profiling in PsA patients and on the pathogenic
features typically associated with PsA such as inflammation,
activation of innate and adaptive immunity (particularly T-
cells), angiogenesis, apoptosis, and bone remodeling [3, 8].
Then, we used the reverse search function of DIANA-
miRPath to find the PsA only active miRNAs significantly
targeting the GO terms of interest. For each miRNA, the
percentages of genes targeted in the selected BPs were
represented in the heat-map of Figure 4. Interestingly, we
found a restricted group of 11 miRNAs (miR-126-3p, miR-
151a-5p, miR-130a-3p and miR-199a-3p, miR-199a-5p, miR-
148a-3p, miR-192-5p, miR-186-5p, miR-331-3p, miR-92a-3p,
miR-17-5p) with experimentally validated targets for the
vast majority of the selected BPs. It is important to note
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Figure 3: Comparison of deregulated miRNAs target genes with PsA-associated transcriptional profiles. (a) Pie chart showing percentages
of DEGs in PsA from [8] not targeted or targeted by PsA only active and PsA common deregulated miRNAs. DEGs targeted by two or more
miRNAs with different modulation in PsA (up- and downmodulated) are defined as “targeting: both opposite and concordant.” (b) Protein-
protein interaction (PPI) network of DEGs in PsA patients (from [8]). (c) Modules originated from the interaction network. Genes targeted
by deregulated miRNAs are highlighted in red.
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Figure 4: Heat-map of biological processes and deregulated miRNAs in PsA. The heat-map shows the percentage of genes targeted by PsA
only activemiRNAs in the GO biological processes selected. The miRNAs are ordered for the absolute values of fold change according to the
microarray analysis.
that, within this subset, miR-126-3p, miR-151a-5p, miR-130a-
3p, and miR-199a-3p had the highest fold changes in our
microarray analysis.
3.5. Validation of Deregulated miRNAs by Real-Time PCR.
Selected miRNAs significantly deregulated in the microarray
analysis were validated by real-time PCR in the entire series
of patients analyzed.We focused onmiRNAs belonging to the
restricted group of 11 PsA only active miRNAs identified as
targeting biological processes altered in PsA (Figure 4) and
with a high FC in the microarray analysis (FC > |10|). Based
on these criteria, we selected miR-126-3p, miR-151a-5p, miR-
130a-3p, andmiR-148a-3p for PCR validations.
A significant downmodulation of all the selectedmiRNAs
in active PsA samples was confirmed, albeit with lower FC
than microarray data (Figure 5(a)). In addition, real-time
PCR analysis revealed that miR-148a-3p was significantly
downregulated also in remission samples as compared to
healthy controls.The expression of themiRNAswas also eval-
uated in 7 PBMC samples derived from RA to verify whether
their underexpression could be also associated with other
inflammatory arthritides. We found that miR-126-3p, miR-
148a-3p, and miR-130a-3p were significantly underexpressed
also in RA samples (Figure 5(a)).
Furthermore, since miR-126-3p was the miRNA with the
highest FC in our series of patients, we decided to perform a
real-time PCR analysis in an expanded panel of PsA patients
and control healthy donors. We confirmed that miR-126-
3p expression was significantly reduced in the expanded
group of active PsA samples (11 patients) as compared to
healthy controls (15 subjects) (FC: −3.7; Figure 5(b)). In
addition, we found that miR-126-3p reduced expression in
remission patients (12 subjects) was statistically significant in
the expanded cohort (FC: −1.9). Interestingly, higher miR-
126-3p expression levels were detected in remission samples
when compared to active PsA (FC: 1.9) (Figure 5(b)).
3.6. Identification of Novel miR-126-3p Targets. A precise role
for miR-126 in PsA has not been identified so far. Since
miR-126-3p expression was reduced in PBMC of active PsA
patients and its level was raised in nonactive patients, we can
speculate that this miRNAmay have an important regulatory
function in the disease.
We therefore sought for putative miR-126 targets with a
potential role in PsA pathogenesis. To this purpose, we per-
formed an analysis with TargetScan software, a bioinformat-
ics tool able to predict putative miRNA targets by searching
for the presence of 3󸀠 untranslated region sites that match
the seed sequence of each miRNA [29]. We narrowed down
the analysis on novel predicted gene targets that belong to
molecular pathways relevant for PsA pathogenesis. Thus, we
selected these four potential targets: v-akt murine thymoma
viral oncogene homolog 2 (AKT2), protein phosphatase 3
catalytic subunit beta (PPP3CB), tumor necrosis factor ligand
superfamily member 11 (TNFSF11, also known as RANKL),
and syndecan 2 (SDC2) genes (Supplementary Table 10).
To assess whether miR-126-3p was able to regulate these
putative target genes, we transfected the T-cell leukemia cell
BioMed Research International 11
miR-126-3p miR-151a-5p miR-130a-3p miR-148a-3p
H
ea
lth
y
Ps
A
 ac
tiv
e
Ps
A
 n
on
ac
tiv
e
RA
H
ea
lth
y
Ps
A
 ac
tiv
e
Ps
A
 n
on
ac
tiv
e
RA
H
ea
lth
y
Ps
A
 ac
tiv
e
Ps
A
 n
on
ac
tiv
e
RA
H
ea
lth
y
Ps
A
 ac
tiv
e
Ps
A
 n
on
ac
tiv
e
RA
0
0.01
0.02
0.03
0.04
0.05
0.06
m
iR
14
8a
-3
p/
m
iR
-1
6-
26
0
0.008
0.016
0.024
0.032
0.04
0.048
m
iR
-1
30
a-
3p
/m
iR
-1
6-
26
0
0.01
0.02
0.03
0.04
0.05
0.06
m
iR
15
1a
-5
p/
m
iR
-1
6-
26
0
0.07
0.14
0.21
0.28
0.35
0.42
m
iR
-1
26
-3
p/
m
iR
-1
6-
26
∗
∗∗
∗ ∗
∗ ∗
∗∗
∗∗
(a)
miR-126-3p
H
ea
lth
y
Ps
A
 ac
tiv
e
Ps
A
 n
on
ac
tiv
e
0
0.09
0.18
0.27
0.36
0.45
0.54
m
iR
-1
26
-3
p/
m
iR
-1
6-
26
∗
∗∗
∗∗∗
(b)
miR-126-3p
N
eg
 C
tr
l
m
iR
-1
26
-3
p0
500
1,000
1,500
2,000
2,500
Fo
ld
 ch
an
ge
∗∗∗
(c)
N
eg
 C
tr
l
PI
K3
R2
A
KT
2
PP
P3
CB
RA
N
KL
SD
C2
Mimic control
Mimic miR-126-3p
0
0.2
0.4
0.6
0.8
1
Fo
ld
 ch
an
ge
∗
∗
∗
∗∗
∗∗
(d)
Figure 5: Validation of differentially expressed miRNAs by real-time PCR. (a) Real-time PCR for the indicated miRNAs were performed in
healthy controls (Healthy), PsA active, and nonactive samples included in the microarray and in 7 patients affected by RA. (b) Real-time PCR
for miR-126-3p in an expanded cohort of healthy (15 patients), PsA active (11 patients), and PsA nonactive (12 patients) groups. Values are
calculated withΔCtmethod. miR-16-5p andmiR-26a-5p were used as endogenous controls for miRNA expression (see Methods). Histograms
indicate mean values; bars indicate standard deviation (SD). ∗𝑝 ≤ 0.05; ∗∗𝑝 ≤ 0.01; ∗∗∗𝑝 ≤ 0.001 (Mann–Whitney rank sum test). (c) Real-
time PCR expression of miR-126-3p in Jurkat cells after 48 h from transfection with miRNAmimics. miR-16-5p andmiR-26a-5p were used as
endogenous controls. (d) Identification of novel miR-126-3p targets. Real-time PCR expression of the indicated transcripts inmimicmiR-126-
3p-transfected and control cells. Beta-Actin was used as endogenous control. Values were calculated with ΔΔCt method as fold change with
respect to mimic negative control-transfected samples. All the histograms indicate mean values of at least three independent experiments;
bars indicate standard deviation (SD). ∗𝑝 ≤ 0.05; ∗∗𝑝 ≤ 0.01; ∗∗∗𝑝 ≤ 0.001 (Student’s 𝑡-test).
line Jurkat with a miR-126-3p mimic and we evaluated the
impact of its ectopic expression on AKT2, PPP3CB, RANKL,
and SDC2 transcript levels. We used PIK3R2 as positive
control of the miRNA mimic, since it is a well-known miR-
126-3p target [30]. After 48 hours from transfection,miR-126-
transfected cells expressed significantly lower levels of all the
targets as compared to themimic control (Figure 5(d)).These
results indicate thatmiR-126-3pmay control the expression of
these genes by the downregulation of their transcripts.
4. Discussion
A systematic analysis of miRNA expression profiles in PsA
has not been performed yet; in particular, it is not known
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whether the global miRNA expression varies in the active
disease when compared to the disease in remission phase.
We therefore analyzed global miRNA expression profiles
in patients with active PsA and in patients that were in a
remission phase of the disease, to identifymiRNAs associated
with PsA and, eventually, miRNAs specifically associated
with the active stage of the disease. By this approach, we
were able to distinguish three subsets of miRNAs that were
differentially expressed only in active (PsA only active) or
only in nonactive PsA (PsA only nonactive) or that are
commonly deregulated in the two conditions (PsA common).
Interestingly, miRNAs belonging to the last group were con-
sensually modulated in active and in nonactive PsA and we
found that all the miRNAs subsets mostly targeted signaling
pathways that have been already described in PsA, including
pathways associated with proteoglycans metabolism [20].
Moreover, modulated miRNAs in PsA targeted pathways
with a potential implication for the disease, related to the
immune system and to crucial signaling pathways governing
cell proliferation and/or apoptosis.
Noteworthy, we found that TNF, MAPK, and WNT
signaling pathways, which have been implicated in PsA
pathogenesis [8], were significantly targeted by miRNAs
modulated only in the active form of the disease. TNF signal-
ing pathway plays a crucial role in PsA and therapeutic TNF
neutralization is a commonplace practice in the treatment
of the disease [1]. Interestingly, different members of MAP
kinase pathwaywere described as upregulated in blood and in
inflamed synovial samples derived from PsA patients [8] and
the p38 MAPK signaling pathway has been associated with
psoriasis and PsA [31].Moreover, theWNT signal cascade has
been implicated in synovial inflammation and in pathological
bone remodeling [32]. In addition, altered expression of
several members of WNT signaling pathway has been also
demonstrated in PsA patients [8].
We also observed that the KEGG pathway “proteoglycans
in cancer” was significantly targeted by all the subsets of
modulated miRNAs, and it was the top enriched pathway
in PsA only active miRNAs subset. Although the pathway is
typically associated with many types of cancers, proteogly-
cans play key roles in angiogenesis, in extracellular matrix
metabolism and in themigration and retention of leukocytes,
whose deregulation is hallmarks of chronically inflamed
synovium typical of PsA [20]. Among gene targets of PsA
only activemiRNAs belonging to this pathway, AKT1, FGF2,
WNT3, WNT5A, and TWIST2 are involved in active bone
and cartilage development and in bone remodeling,which are
typical features of the active disease. This finding suggested
that proteoglycans metabolism could be importantly affected
by miRNAs deregulation in PsA, in particular during the
active phase of the disease.
Our data prettywell correlated to the resultswe previously
published describing gene modulation associated with PsA
patients [8]. Indeed, ∼43% of differentially expressed genes
(DEGs) that we described in PsA were targeted bymodulated
miRNAs that we identified in the present work. These genes
included molecules that play important role in the PsA
pathogenesis and that were upregulated in our previous
analysis (i.e., TNF-alpha, SPP1, and IL6ST). Interestingly, all
these molecules were targeted by downmodulated miRNAs
like miR-130a-3p (TNF-alpha, IL6ST), miR-126-3p (SPP1),
and miR-192-5p (IL6ST); this was coherent with the typical
miRNA action as negative regulator of gene expression (i.e.,
overexpressed genes are targeted by downregulated miRNAs
and downmodulated genes are targeted by upregulated miR-
NAs).
TNF-alpha is involved in a number of autoimmune/
inflammatory diseases and is one of the major proinflam-
matory factors in arthritis causing joint inflammation and
cartilage destruction. Furthermore, TNF level is increased
both in the synovium and in the synovial fluid of PSApatients
[6].
We have previously demonstrated that high serum levels
of SPP1 were detectable in PsA and in other inflammatory
arthritides [8]. Thus, downregulation of miR-126-3p could
explain, at least in part, themolecular mechanism underlying
the upregulation of SPP1 in PsA. Finally, IL6ST has a key role
in the differentiation ofTh17 cells and was found upregulated
in PsA patients [8].
To prioritize modulated genes in PsA that may play a
prominent role in the pathogenesis of this disease, the results
of our previous gene expression analysis were submitted
to a network analysis and we identified five modules that
included the most highly connected genes. The functional
enrichment analysis of modules confirmed their involvement
in biological processes and pathways that are crucial in
the PsA pathogenesis including type I interferon signaling,
inflammatory response, extracellular matrix organization,
regulation of activated T-cell proliferation, T-helper 17 cell
(Th-17) immune response, TNF-alpha production and Toll-
like receptors, p38 MAPK, and B-cell activation signaling
pathways. Interestingly, in each module, we found genes that
are targets of miRNAs modulated in PsA.
These results strengthen the pathogenetic relevance of
some miRNAs since they target components of modules
where genes associated with an autoimmune response are
strictly connected, including genes associated with IFN
response, or withTh-17 cell immune response.
In particular, beside SPP1 and IL6ST, modulatedmiRNAs
targeted important genes in modules like SDC2, SDC4,
CXCL2, and MMP9.
CXCL2 is another target with a potential interest, since
it is a chemokine produced by monocytes and macrophages
following stimulation by IL-17. Besides its role as chemoat-
tractingmolecule for neutrophils, CXCL2has been associated
with increased osteoclastogenesis in rheumatoid arthritis-
associated bone erosion [33]. The matrix metalloprotease
MMP9 expression is found elevated in arthritis and this
enzyme degrades noncollagen matrix component of the joint
[34].
In particular, we observed that the twomodules that were
involved in glycosaminoglycan metabolism and extracellular
matrix organization, whose alteration is crucial in the patho-
genesis of inflammatory arthritis [8], were mostly impacted
by modulated miRNAs. Indeed, among other modules, they
included the highest number of gene targets. Moreover,
considering that proteoglycans in cancerwere the top enriched
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pathway for PsA only active miRNAs, it is tempting to spec-
ulate that epigenetics dysregulation mediated by miRNAs
could exert a major influence in proteoglycans metabolism
and extracellular matrix organization in PsA. Indeed, some
evidence in literature suggests a role for miRNAs in the reg-
ulation of extracellular matrix degradation in osteoarthritis
chondrocytes [35]. In addition, it is known that miRNAs play
an important role in inflammatory response, synovial cell
proliferation, and production of matrix metalloproteases in
RA synovial tissues [11]. Further studies would be needed
to better clarify the role of miRNAs in cartilage and bone
remodeling in PsA.
We then focused our attention on PsA only active subset
and searching formiRNAs thatmay target relevant functional
classes that we found altered in our previous gene expression
analysis. We could select 11 miRNAs that targeted the vast
majority of selected BPs and, among these,miR-126-3p,miR-
151a-5p, miR-130a-3p, and miR-199a-3p showed the highest
fold changes.
A precise role for the above-mentioned miRNAs in
inflammatory arthritides has not been clearly elucidated yet.
Some evidence indicates that miR-126 can regulate vascular
integrity and angiogenesis by downregulating SRED1 and
PIK3R2 [36], and vascular changes typically occurred in joint
lesions of PsA [1, 3]. Interestingly, a decreased expression
of miR-130a has been shown to correlate with TNF-𝛼 in
the development of osteoarthritis [37]. Elevated expression
of miR-151a-5p was found in solid tumors, in which it can
induce proliferation and epithelial-mesenchymal transition
[38] but, so far, there is no evidence about its potential role in
inflammatory arthritides. miR-199a-3p plays a role in skeletal
development and in chondrogenesis targeting SMAD1 [39]
although its role in PsA has not been investigated yet.
The PsA only active miRNAs miR-126-3p, miR-151a-5p,
miR-130a-3p, andmiR-148a-3pwere selected for validation by
real-time PCR in the entire cohort of patients. The trend of
modulation, besides quantitative differences in fold changes,
was confirmed for all the miRNAs tested.
Interestingly, when these miRNAs were tested in PBMC
from RA patients we found thatmiR-126-3p andmiR-130a-3p
were significantly underexpressed in these samples.
In addition, the reduced expression of miR-126-3p in
active PsA compared to both nonactive PsA and healthy
condition was confirmed in an expanded group of patients
suggesting that blood miR-126-3p expression could correlate
with the disease phase in PsA. Importantly, when transfected
in T-cell leukemia cell line Jurkat, miR-126-3p was able to
regulate the expression ofAKT2,PPP3CB,RANKL, and SDC2
genes that were selected among potential target of miR-126-
3p that may be relevant for the PsA pathogenesis.
AKT2 belongs to AKT subfamily of serine/threonine
kinases containing SH2-like domains. It participates in the
PIK3/AKT/mTOR signaling pathway as a critical mediator
of survival signals in different contexts, including PsA where
deregulated proliferation and aberrant survival of activated
immune cells, macrophages, monocytes, dendritic cells, and
synovial fibroblasts occurs [40].
TNFSF11, also known as RANKL, is a member of TNF
superfamily that binds RANK on the surface of precursors
and mature osteoclasts promoting differentiation and cell
activation. RANKL/RANK signaling regulates osteoclast for-
mation, activation, and survival in normal bone modeling
and in a variety of pathologic conditions characterized by
increased bone turnover. Interestingly, RANKL is expressed
by infiltrating T cells and synovial fibroblastoid cells in the
inflamed joints of PsA, and a dramatic increase of RANKL
in the synovial lining layer has been proposed to explain the
pathological bone erosion in the disease [3].
As described above, SDC2 is a component of syndecan
proteoglycan family that we found upregulated in blood and
in synovial biopsies of PsA [8]. An upregulation of SDC2
has been also reported in chronically inflamed synovia of
different forms of arthritis, in particular in endothelial cells,
pericytes, and smooth muscle cells in which it can play a
role in several pathomechanisms such as angiogenesis and
migration and retention of leukocytes [20].
PPP3CB represents the catalytic beta subunit of cal-
cineurin, a calmodulin-dependent serine/threonine protein
phosphatase with a key role in T-cell activation [41]. Aberrant
T-cell activation has a central role in PsA; indeed, conven-
tional DMARDs used in PsA therapy such as cyclosporine
act as calcineurin inhibitors. Altogether, our results suggest
that the reduced expression of miR-126-3p in PsA may
have important functional consequences upon regulation of
crucial effector molecules implicated in the disease.
In conclusion, this work represents the first study which
combines a comprehensive miRNA expression profiling with
a transcriptome analysis in PsA. By microarray analysis, we
identified specific miRNA expression profiles that character-
ize PsA patients both in active disease and in remission phase.
The identifiedmiRNAs target key signaling pathways relevant
in PsA. Network and modules analyses on differentially
expressed genes in PsA showed that selected miRNAs regu-
lated highly connected genes within the PsA transcriptome.
Among the identified miRNAs, the highest level of reduction
was observed for miR-126-3p. Importantly, miR-126-3p was
selectively downregulated in active PsA patients, whereas
its expression was higher in patients in remission phase.
miR-126 overexpression induced a decrease of important
molecular targets with a relevant role in PsA pathogenesis.
This study sheds light on some epigenetic aspects of PsA
pathogenesis identifying deregulated miRNAs, which may
represent promising candidates for the identification of dis-
ease biomarkers and/or for the design of novel therapeutic
strategies in PsA.
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